Detalhe da pesquisa
1.
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
N Engl J Med
; 383(12): 1139-1148, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877599
2.
Long-term outcomes of stage IIB-IV melanoma patients: nationwide data from Norway.
Future Oncol
; 19(3): 205-215, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974621
3.
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
Int J Cancer
; 150(1): 100-111, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34449877
4.
Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
Br J Cancer
; 124(3): 574-580, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33087895
5.
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med
; 377(19): 1813-1823, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891408
6.
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(5): 701-710, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30928620
7.
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.
Lancet Oncol
; 18(5): 611-622, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28359784
8.
A man in his sixties with dyspnoea following immunotherapy. / En mann i 60-årene med dyspné etter immunterapi.
Tidsskr Nor Laegeforen
; 141(2021-12)2021 09 07.
Artigo
em Inglês, Norueguês
| MEDLINE | ID: mdl-34505469
9.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med
; 367(2): 107-14, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22663011
10.
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Lancet Oncol
; 14(8): 733-40, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23735514
11.
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.
Cancer Immunol Immunother
; 62(9): 1499-509, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23817721
12.
Malignant melanoma--diagnosis, treatment and follow-up in Norway.
Tidsskr Nor Laegeforen
; 133(20): 2154-9, 2013 Oct 29.
Artigo
em Inglês, Norueguês
| MEDLINE | ID: mdl-24172628
13.
Pilot Study of ONCOS-102 and Pembrolizumab: Remodeling of the Tumor Microenvironment and Clinical Outcomes in Anti-PD-1-Resistant Advanced Melanoma.
Clin Cancer Res
; 29(1): 100-109, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36112545
14.
Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma.
J Clin Invest
; 133(6)2023 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36719749
15.
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
J Clin Oncol
; 41(24): 3998-4003, 2023 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37348035
16.
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.
J Clin Oncol
; 41(15): 2724-2735, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-36780608
17.
AXL inhibition improves BRAF-targeted treatment in melanoma.
Sci Rep
; 12(1): 5076, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35332208
18.
Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial.
Front Immunol
; 12: 663865, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34046035
19.
Soluble AXL as a marker of disease progression and survival in melanoma.
PLoS One
; 15(1): e0227187, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-31917795
20.
Long-Term Outcomes of a Phase I Study With UV1, a Second Generation Telomerase Based Vaccine, in Patients With Advanced Non-Small Cell Lung Cancer.
Front Immunol
; 11: 572172, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33324397